Ivarmacitinib

• Arcutis Biotherapeutics' ZORYVE franchise achieved $44.8 million in net product revenues in Q3 2024, marking a 452% increase compared to Q3 2023, driven by strong demand for both cream and foam formulations. • The FDA accepted the sNDA for ZORYVE foam for scalp and body psoriasis, with a PDUFA action date of May 22, 2025, potentially expanding the drug's approved indications. • Health Canada approved ZORYVE foam for seborrheic dermatitis, with commercial launch planned by the end of 2024, extending the drug's availability to international markets. • Arcutis is advancing its pipeline with the completion of enrollment in the ARQ-255 alopecia areata phase 1 trial and progress towards an IND for ARQ-234 in atopic dermatitis.

• The Janus Kinase (JAK) inhibitor pipeline is actively being developed by multiple companies, showing promise in treating various autoimmune and inflammatory diseases. • Key companies such as Incyte, AbbVie, and Bristol Myers Squibb are advancing JAK inhibitor therapies through clinical trials and regulatory submissions. • Emerging therapies like povorcitinib, upadacitinib, and deucravacitinib have demonstrated efficacy in treating conditions like hidradenitis suppurativa, axial spondyloarthritis, and plaque psoriasis. • The JAK inhibitor market is driven by the rising prevalence of chronic diseases and substantial investments in research and development, offering targeted treatment approaches.